Patients
| Preclinical | Phase 1 | Phase 2 | Phase 2b | Phase 3 | |
|---|---|---|---|---|---|
| Systemic Sclerosis |
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 2b Phase complete
|
Phase 3 Phase in progress
|
|
| Cystic Fibrosis |
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 2b Phase in progress
|
Phase 3 Phase not started
|
|
| Dermatomyositis |
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
|
| Systemic Lupus Erythematosus |
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus
To learn more about each of our ongoing studies, please click on one of the below links.